MSC vs exosomes for Alzheimer's Disease: what the registries show
For Alzheimer's Disease, the registry holds 23 MSC records against 10 exosomes records. MSC carries the larger research programme; neither column is a head-to-head efficacy result. Snapshot 2026-08-29.
Side by side
| Metric | MSC | exosomes |
|---|---|---|
| Registered studies | 23 | 10 |
| Recruiting now | 6 | 1 |
| Phase 3 or 4 records | 0 | 0 |
| Completed | 6 | 2 |
| Stopped early | 1 | 0 |
| Countries with sites | 4 | 5 |
| Median planned enrolment | 21 | 58 |
| First registration year | 2,011 | 2,014 |
The condition underneath the comparison
Alzheimer's involves amyloid and tau pathology, synaptic loss and chronic neuroinflammation years before diagnosis. Cell and exosome approaches target the inflammatory and trophic side rather than removing plaques. The hard problem is delivery across the blood-brain barrier and the fact that by the time symptoms are obvious, substantial neuronal loss has already happened.
MSC: what it is
Mesenchymal stromal cells are the workhorse of commercial cell therapy: easy to source from fat, cord or marrow, easy to expand, and rarely characterised in the same way twice. Their proposed action is paracrine — signalling molecules that damp inflammation — rather than replacement of lost tissue. That matters when reading counts like these, because two studies filed under the same label can test materially different products at different doses by different routes.
exosomes: what it is
Exosome and extracellular-vesicle products are cell-free: vesicles harvested from cultured cells and given without the cells themselves. They are attractive commercially because they avoid live-cell logistics, and they are regulatorily contested for the same reason — several regulators have issued explicit warnings about unapproved exosome products marketed for human use.
Maturity difference
MSC has 0 Phase 3/4 records and 6 completed studies; exosomes has 0 and 2. Where both sit early on the ladder, the honest answer to "which works better" is that registrations cannot tell you.
Leading MSC studies
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT07367815 — Allogeneic Adipose Tissue Derived-stem Cells in Alzheimer Disease | Phase 1, Phase 2 | Recruiting | 9 | University Hospital, Toulouse | 2026-05-07 |
| NCT07512362 — Human Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease. | Phase 2 | Recruiting | 10 | Bernard (Barry) Baumel | 2026-05-15 |
| NCT06775964 — Stem Cell Therapy for Early Alzheimer's Disease | Phase 1, Phase 2 | Recruiting | 12 | Paul E Schulz | 2026-03-11 |
| NCT07457125 — The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease | Phase 1, Phase 2 | Recruiting | 33 | Xuanwu Hospital, Beijing | 2026-05-30 |
| NCT06781333 — Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease. | Phase 2 | Recruiting | 8 | Bernard (Barry) Baumel | 2025-04-29 |
Leading exosomes studies
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT07457125 — The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease | Phase 1, Phase 2 | Recruiting | 33 | Xuanwu Hospital, Beijing | 2026-05-30 |
| NCT04388982 — the Safety and the Efficacy Evaluation of Allogenic Adipose MSC-Exos in Patients With Alzheimer's Disease | Phase 1, Phase 2 | Unknown | 9 | Ruijin Hospital | 2020-07-01 |
| NCT01811381 — Curcumin and Yoga Therapy for Those at Risk for Alzheimer's Disease | Phase 2 | Unknown | 80 | VA Office of Research and Development | 2014-01-20 |
| NCT07554872 — Study of Neural Stem Cell-Derived Exosomes in Moderate-to-Severe Early-Onset Alzheimer's Disease | Phase 1 | Not Yet Recruiting | 9 | Shanghai Mental Health Center | 2026-05 |
| NCT06774261 — Phenserine on the Alzheimer's Treatment Horizon, Study 1 | Phase 1 | Completed | 16 | Helse Stavanger HF | 2025-02-01 |
The honest comparison
Head-to-head trials putting these two approaches in the same protocol are rare or absent for most conditions. Comparing counts from separate registry queries shows where research effort went — driven by cost, regulation and sponsor interest as much as by biology. Anyone presenting one column of this table as proof of superiority is overreading it.
Frequently asked
Is MSC better than exosomes for Alzheimer's Disease?
The registries cannot answer that. They show research volume and maturity, not comparative effectiveness: 23 vs 10 registered records (2026-08-29).
Which has more late-stage research for Alzheimer's Disease?
MSC: 0 Phase 3/4 records. exosomes: 0.
Can a clinic offer both?
Some do, which is itself worth questioning — a provider offering every modality for every condition is describing a business model, not a treatment rationale.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.